1. Jazz Pharmaceuticals (NASDAQ: JAZZ)
Jazz Pharmaceuticals (NASDAQ: JAZZ) takes the top spot on our list of the best cheap biotech stocks to buy now, supported by strong analyst confidence and a diversified portfolio of therapies targeting serious diseases. Jazz develops treatments for neurological disorders, oncology, and rare diseases, with products such as Xywav, Epidiolex, and Zepzelca forming the core of its commercial portfolio.
Barclays initiated coverage with an Overweight rating and a $224 price target, citing the company’s durable central nervous system franchise and long-term oncology growth potential.
Morgan Stanley, Deutsche Bank, and Bank of America also raised their price targets following the company’s recent earnings report, reflecting growing optimism about Jazz’s pipeline and commercial expansion.
Analysts believe the company’s oncology therapy Ziihera could become a major growth driver as it expands into additional tumor indications, potentially transforming Jazz Pharmaceuticals into one of the most dynamic growth stories within the biotechnology sector.
READ ALSO: Top 5 Best Biotech Stocks of February 2026 and Lexicon Pharmaceuticals (LXRX) Proves That Boring Science Can Still Move Markets.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
